英諾賽科(02577.HK)折讓近9%配股 淨籌5.44億元
英諾賽科(02577.HK)宣佈於7月22日與配售代理訂立協議,計劃配售1,358.4萬股新H股,佔經擴大後H股及總股本約2.69%及1.52%,每股配售價爲40.5元,較前一日收市價44.45元折讓約8.89%,預料集資淨額約5.44億元。
所得資金有約50%將用於產品升級迭代,拓展新產品應用的技術研發以增強產品競爭力,提高氮化鎵產品在終端市場的滲透率;約25%用於償還現有銀行有息負債;約25%用於補充流動資金和一般營運用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.